Press Room
What is the media saying about us? Press articles, interviews and other appearances on radio and TV. Access to resources for journalists: Photo Gallery and Press Dossier.
Press contact: comunicacion@algenex.com
What is the media saying about us? Press articles, interviews and other appearances on radio and TV. Access to resources for journalists: Photo Gallery and Press Dossier.
Press contact: comunicacion@algenex.com
The European Comission has granted marketing approval to a rabiit hemorrhagic disease virus (RHVD) from Italian business Fatro. The vaccine incorporates CrisBio technology developed by Spain´s Algenex.
Madrid-based company Algenex is using moths as natural bioreactors to improve the speed and scalability of making proteins used in vaccines and diagnostics.
The initial idea for ALGENEX was developed at a conference in Canada in the 1990s. Conversing with an American colleague in a Poxvirus meeting, we realised the huge potential for the use of living organisms in the production of recombinant proteins, and from that conversation, we began collaborating.